L. Estévez

C. Gridelli, A. Falcone, R. Mattioli, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Sung-Bae Kim, J. Baselga, A. Bardia, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

D. Juric, M. Campone, P. Munster, 2015 .

Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.

D. Juric, M. Campone, I. Mayer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

M. Hidalgo, S. Perea, I. Calvo, 2014, Breast Cancer Research.

Current controversies in the management of early breast cancer

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

J. Albanell, A. Lluch, B. Cirauqui, 2012, Breast Cancer Research and Treatment.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

P. Fasching, E. Winer, P. V. van Dam, 2019, Clinical Cancer Research.

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

E. Winer, P. Morris, I. C. Tudor, 2017 .

Neoadjuvant endocrine therapy for breast cancer: past, present and future

L. Calvo, A. Barnadas, P. Sánchez‐Rovira, 2008, Anti-cancer drugs.

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Sung-Bae Kim, S. Loi, A. Bardia, 2020 .

HER2-Positive Breast Cancer

A. Seidman, L. Estévez, 2003 .

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).

Sung-Bae Kim, A. Bardia, Chiun-Sheng Huang, 2015 .

SEOM clinical guidelines in early-stage breast cancer 2015

S. Servitja, M. Margelí, J. García-Saenz, 2015, Clinical and Translational Oncology.

A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

M. Provencio, P. Sánchez‐Rovira, M. Dómine, 2008, Clinical breast cancer.

Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy

P. Martínez, M. Provencio, A. Barnadas, 1999, Cancer Chemotherapy and Pharmacology.

Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.

M. Dómine, A. Leon, M. Lomas, 2003, Clinical breast cancer.

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

Á. Rodríguez-Lescure, A. Barnadas, P. Sánchez‐Rovira, 2011, Advances in therapy.

Neoadjuvant chemotherapy in breast cancer

L. Estévez, Laura G. Estévez, 2004 .

SECCIÓN DOCENTE Neoadjuvant chemotherapy in breast cancer

L. Estévez, 2022 .

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

P. Sánchez‐Rovira, M. Dómine, I. Calvo, 2004, Seminars in oncology.

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.

A. Antón, A. Herrero, J. López-Vega, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study

M. Margelí, E. Adrover, E. Castellà, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials.

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical breast cancer.

Current perspectives of treatment of ductal carcinoma in situ.

A. Lluch, I. Tusquets, M. Margelí, 2010, Cancer treatment reviews.

Optofluidic device for the quantification of circulating tumor cells in breast cancer

A. Ródenas, R. Álvarez-Puebla, L. Guerrini, 2017, Scientific Reports.

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

E. Carrasco, P. Sánchez‐Rovira, M. Dómine, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.

A. Lluch, I. Tusquets, M. Margelí, 2008, Cancer treatment reviews.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

M. Hidalgo, S. Perea, I. Calvo, 2014, Breast Cancer Research.